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VonWillebrand and Factor VIII Portosystemic Circulation
Gradient in Cirrhosis: Implications for Portal
Vein Thrombosis
Michael Praktiknjo, MD1, Jonel Trebicka, MD2,3,4, Roberto Carnevale, PhD5,6, Daniele Pastori, MD, PhD7, Alexander Queck, MD2,
Evaristo Ettorre, MD8 and Francesco Violi, MD6,7
OBJECTIVES: Portal vein thrombosis seems to be dependent on local hypercoagulation and venous stasis; data
regarding endothelial damage are lacking.
METHODS: vonWillebrad factor, amarker of endothelial damage/perturbation, factor VIII, and lipopolysaccharides
(LPS) were studied in the portal and systemic circulation of 20 cirrhotic patients undergoing
transjugular intrahepatic portosystemic procedure.
RESULTS: vonWillebrad factor, factor VIII, and LPS were higher in the portal compared with systemic circulation,
with a significant correlation between LPS and the other 2 variables.
DISCUSSION: Endothelial damage and hypercoagulation coexist in the portal tree of patients with cirrhosis, and both
could contribute to portal vein thrombosis. LPS may be a potential trigger of endothelial damage.
Clinical and Translational Gastroenterology 2020;11:e00123. https://doi.org/10.14309/ctg.0000000000000123
INTRODUCTION
There is a growing body of evidence to suggest that liver cirrhosis
is associated with portal vein thrombosis (PVT), which may be
detected in approximately 17% of the patients (1,2). The mech-
anisms accounting for PVT have not been fully elucidated. Risk
factors such as factor V Leiden, prothrombin G20210 mutations,
and splenectomy may account for PVT (3). According to the
Virchow triad, local factors such as hypercoagulation, venous
stasis, and endothelial damage may be also determinants for ve-
nous thrombosis; 2 of them, namely venous stasis and hyper-
coagulation, have been detected in the portal circulation of
cirrhotic patients. In particular, Stine et al. (4) have recently
reported that a portal flow,15 cm/s predisposes to PVT and its
recurrence. We previously reported enhanced thrombin gener-
ation in the portal compared with systemic circulation; such
a change was suggested to be dependent on an elevated concen-
tration of lipopolysaccharides (LPS) in the portal circulation (5).
Conversely, it is not known whether endothelial damage is also
detectable in the portal tree. To address this issue, we measured
blood levels of von Willebrand factor (vWF), which is a recog-
nized marker of endothelial damage/perturbation (6), in the
portal and systemic circulation of cirrhotic patients undergoing
transjugular intrahepatic portosystemic shunt (TIPS) procedure.
METHODS
Twenty patients with decompensated cirrhosis diagnosed by
clinical, imaging, or histologic finding and undergoing TIPS
procedure were included in the study. Among them, 8 had ascites
and 12 had variceal bleeding. Blood from the portal and the he-
patic vein was collected as previously described (7). Briefly, first
central venous blood was taken, and thereafter, blood sample
from the portal vein was taken immediately after puncture of the
vein, but before dilatation of the tract or insertion of the TIPS-
stent portal, the venous samples were taken. After discarding, 5
mL blood was collected in tube with or without anticoagulant
(3.8% sodium citrated) and centrifuged at 300 g for 10 min at
room temperature. The supernatants were collected and stored at
280 °C up to 5 years. The concentration of vWF, factor VIII, and
LPS from Escherichia Coli was determined as previously de-
scribed (8) by enzyme-linked immunosorbent assay (Abnova,
KA0512, Taipei, Taiwan; Lifespan Bioscience, LS-F10415,
Washington and Cusabio, CSB-E09945h, Houston, TX; re-
spectively). The enzyme-linked immunosorbent assay kit is
designed for the detection of monoclonal antibody specific for
vWF and factor VIII and E. Coli-LPS expressed in units per
deciliter dor vWF and factor VIII and pg/mL for LPS. Inter- and
intra-assay coefficients of variations were,10%.
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The local ethics committee of theUniversity of Bonn approved
the study (029/13), and all patients signed an informed written
consent in accordance with the Helsinki Declaration for the
procedures they underwent.
Statistical analysis
Comparisons between vWF, LPS, and factorVIII in the portal and
systemic circulation were carried out by Mann–Whitney test for
unpaired samples, and data are expressed as median and inter-
quartile ranges (IQR). The Spearman rank correlation coefficient
(rS) was used for bivariate correlation.
RESULTS
The median age was 57 (IQR 41–74) years and 13 patients were
men. Medianmodel for end-stage liver disease was 14 (IQR 8–34);
4 patients were staged Child Turcotte Pugh (CTP) A, 14 were CTP
B, and 2were CTPC. Eleven patients had alcoholic etiology of liver
cirrhosis. Indication for TIPS was variceal bleeding in 9 and re-
fractory ascites in 11 patients. Although there was no significant
correlation with the scores of liver disease severity (model for end-
stage liver disease, CTP), we found a portal/systemic circulation
gradient for all the 3 variables investigated: vWF (250.0 [IQR
214.0–267.0] vs 180.0 [IQR 161.0–204.0] U/dL, P, 0.001), factor
VIII (164.0 [IQR 152.0–180.0] vs 112.0 [IQR 97.0–127.0] U/dL,
P, 0.001), and LPS (56.5 [IQR 50.5–65.0] vs 43.0 [IQR 36.3–45.0]
pg/mL, P , 0.001) were higher in the portal compared with sys-
temic circulation (Figure 1a–c). Furthermore, LPSwas significantly
correlated with vWF (rS:0.400, P5 0.01) and factor VIII (rS:0.360,
P 5 0.02) (Figure 1d,e). Interestingly, we found a higher porto-
systemic gradient of vWF in patients with ascites as indication for
TIPS comparedwith variceal bleeding (hepatic–portal: 81.16 38.4
vs241.36 48.5 U/dL, P, 0.05).
DISCUSSION
This study reports for thefirst time the existence of a portosystemic
vWF gradient in cirrhotic patients, suggesting that the portal tree
encompasses local factors predisposing to endothelial damage/
perturbation are detectable in cirrhosis. We focused our attention
onLPS because previous studies reported that LPS is elevated in the
portal circulation of cirrhosis (5) and elicits endothelial perturba-
tion with vWF secretion (8). The significant association between
LPS and vWF is in favor of the hypothesis that LPS is one factor
eliciting endothelial damage in the portal circulation of cirrhosis.
Another interesting finding of the study is the presence of
a portosystemic factor VIII gradient in cirrhosis, which reinforces
a previous study reporting an increased concentration of factor
VIII in the portal circulation of cirrhotic patients compared with
systemic circulation of healthy subjects (9). This finding supports
and extends our previous report showing the existence of
a hypercoagulation state in the portal circulation of cirrhosis (5)
suggesting enhanced factor VIII as an important mechanism pre-
disposing to thehypercoagulation state. LPSmay also be relevant to
this clotting change because it elicits endothelial secretion of factor
VIII at concentrations commonly found in the venous circulation
of cirrhosis (8). Thus, LPS could represent a unique mechanism
which is implicated in enhancing either vWF or factor VIII in the
portal circulation, thus favoring endothelial damage and hyper-
coagulation. However, we cannot exclude that other mechanisms
such as increase of ADAMS 13 or microvesicles, both possessing
procoagulant properties (10), may contribute to hypercoagulation
in the portal circulation of cirrhosis (10,11). Changes in the gut
permeability with consequent translocation of LPS into systemic
circulation may be a factor accounting for the enhanced LPS
concentration in the portal tree, but further study is necessary to
explore this hypothesis. In conclusion, here, we provide evidence in
Figure1.Differences in coagulation and inflammation biomarkers in the portal and systemic circulation. Levels of vWF (a), FVIII (b), and LPS (c) in the portal
and systemic circulation of patients with cirrhosis (n 5 20, **P, 0.001). LPS, lipopolysaccharides; vWF, von Willebrand factor.
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support that endothelial damage is detectable in the portal circu-
lation of cirrhosis and suggest LPS as a mechanism implicated in
this phenomenon; modulation of LPS concentration may be a tool
to reduce the thrombotic risk in cirrhosis (12).
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Study Highlights
WHAT IS KNOWN
3 Cirrhosis is associated with portal vein thrombosis.
3 Ahypercoagulation status is detected in the portal circulation.
WHAT IS NEW HERE
3 Endothelial damage, as assessed by vWF and factor VIII, is
detectable in the portal circulation of cirrhosis.
3 Serum lipopolysaccharides correlate with endothelial
damage suggesting a cause-effect relationship.
TRANSLATIONAL IMPACT
3 This finding provides further insight into the pathogenesis of
portal vein thrombosis and reinforces the concept the
hypercoagulation status does exist in cirrhosis.
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